{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:59:21Z","timestamp":1791143961261,"version":"4.1.0"},"reference-count":104,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    This brief review of current research progress on Charcot-Marie-Tooth (CMT) disease is a summary of discussions initiated at the Hereditary Neuropathy Foundation (HNF) scientific advisory board meeting on November 7, 2014. It covers recent published and unpublished\n                    <ns4:italic>in vitro<\/ns4:italic>\n                    and\n                    <ns4:italic>in vivo<\/ns4:italic>\n                    research. We discuss recent promising preclinical work for CMT1A, the development of new biomarkers, the characterization of different animal models, and the analysis of the frequency of gene mutations in patients with CMT. We also describe how progress in related fields may benefit CMT therapeutic development, including the potential of gene therapy and stem cell research. We also discuss the potential to assess and improve the quality of life of CMT patients. This summary of CMT research identifies some of the gaps which may have an impact on upcoming clinical trials. We provide some priorities for CMT research and areas which HNF can support. The goal of this review is to inform the scientific community about ongoing research and to avoid unnecessary overlap, while also highlighting areas ripe for further investigation. The general collaborative approach we have taken may be useful for other rare neurological diseases.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.6160.1","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T09:50:05Z","timestamp":1424944205000},"page":"53","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["A brief review of recent Charcot-Marie-Tooth research and priorities"],"prefix":"10.12688","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia K.","family":"Litterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e J.G.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Freundlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna E.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Notterpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pleasure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"987-1002","DOI":"10.4155\/fmc.14.65","article-title":"The discovery of medicines for rare diseases.","volume":"6","author":"D Swinney","year":"2014","journal-title":"Future Med Chem."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"16-23","DOI":"10.1378\/chest.13-0606","article-title":"Rare diseases research: expanding collaborative translational research opportunities.","volume":"144","author":"S Groft","year":"2013","journal-title":"Chest."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1043-1051","DOI":"10.1016\/j.drudis.2013.08.006","article-title":"Multifaceted roles of ultra-rare and rare disease patients\/parents in drug discovery.","volume":"18","author":"J Wood","year":"2013","journal-title":"Drug Discov Today."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"736-7","DOI":"10.1038\/gim.2014.23","article-title":"The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated.","volume":"16","author":"M Might","year":"2014","journal-title":"Genet Med."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"5-7","DOI":"10.1001\/jamaneurol.2014.2346","article-title":"The future of research in neuropathy.","volume":"72","author":"T Itoh","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-6-49","article-title":"The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases.","volume":"6","author":"B Miyamoto","year":"2011","journal-title":"Orphanet J Rare Dis."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-7-39","article-title":"A generalizable pre-clinical research approach for orphan disease therapy.","volume":"7","author":"C Beaulieu","year":"2012","journal-title":"Orphanet J Rare Dis."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.12688\/f1000research.3751.2","article-title":"Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.","volume":"3","author":"L Sames","year":"2014","journal-title":"F1000Res."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/nm1014-1080","article-title":"Ice bucket challenge cash may help derisk ALS drug research.","volume":"20","author":"M Vaidya","year":"2014","journal-title":"Nat Med."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"4-15","DOI":"10.1080\/17482960701856300","article-title":"Design, power, and interpretation of studies in the standard murine model of ALS.","volume":"9","author":"S Scott","year":"2008","journal-title":"Amyotroph Lateral Scler."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"423-425","DOI":"10.1038\/507423a","article-title":"Preclinical research: Make mouse studies work.","volume":"507","author":"S Perrin","year":"2014","journal-title":"Nature."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrd3439-c1","article-title":"Believe it or not: how much can we rely on published data on potential drug targets?","volume":"10","author":"F Prinz","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2719-2740","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.","volume":"53","author":"J Baell","year":"2010","journal-title":"J Med Chem."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"481-3","DOI":"10.1038\/513481a","article-title":"Chemistry: Chemical con artists foil drug discovery.","volume":"513","author":"J Baell","year":"2014","journal-title":"Nature."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"913-26","DOI":"10.1021\/ci300005y","article-title":"Chemical and biological properties of frequent screening hits.","volume":"52","author":"J Che","year":"2012","journal-title":"J Chem Inf Model."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"4231-55","DOI":"10.2174\/092986710793348545","article-title":"False positives in the early stages of drug discovery.","volume":"17","author":"R Sink","year":"2010","journal-title":"Curr Med Chem."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"e62325","DOI":"10.1371\/journal.pone.0062325","article-title":"Dispensing processes impact apparent biological activity as determined by computational and statistical analyses.","volume":"8","author":"S Ekins","year":"2013","journal-title":"PLoS One."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1126\/science.1162395","article-title":"Bioactive contaminants leach from disposable laboratory plasticware.","volume":"322","author":"G McDonald","year":"2008","journal-title":"Science."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2406-14","DOI":"10.1021\/jm301749y","article-title":"Colloidal aggregation causes inhibition of G protein-coupled receptors.","volume":"56","author":"M Sassano","year":"2013","journal-title":"J Med Chem."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"708-15","DOI":"10.1177\/1087057109335670","article-title":"Overcoming problems of compound storage in DMSO: solvent and process alternatives.","volume":"14","author":"T Waybright","year":"2009","journal-title":"J Biomol Screen."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"316-24","DOI":"10.1139\/cjpp-2012-0257","article-title":"Triton X-100 inhibits L-type voltage-operated calcium channels.","volume":"91","author":"D Narang","year":"2013","journal-title":"Can J Physiol Pharmacol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"685-701","DOI":"10.1016\/j.drudis.2012.02.013","article-title":"Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation.","volume":"17","author":"A Williams","year":"2012","journal-title":"Drug Discov Today."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"58-70","DOI":"10.1016\/j.drudis.2012.11.005","article-title":"Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.","volume":"18","author":"C Southan","year":"2013","journal-title":"Drug Discov Today."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"661-9","DOI":"10.1038\/nrd3503","article-title":"Minimum information about a bioactive entity (MIABE).","volume":"10","author":"S Orchard","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1-14","DOI":"10.1177\/1087057110389039","article-title":"Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.","volume":"16","author":"T Shun","year":"2011","journal-title":"J Biomol Screen."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"479-83","DOI":"10.1038\/nchembio.180","article-title":"Quantifying biogenic bias in screening libraries.","volume":"5","author":"J Hert","year":"2009","journal-title":"Nat Chem Biol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"265-6","DOI":"10.1016\/j.drudis.2012.10.007","article-title":"Four disruptive strategies for removing drug discovery bottlenecks.","volume":"18","author":"S Ekins","year":"2013","journal-title":"Drug Discov Today."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"409-10","DOI":"10.1038\/nrd3462","article-title":"US academic drug discovery.","volume":"10","author":"S Frye","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"40-51","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs.","volume":"32","author":"M Hay","year":"2014","journal-title":"Nat Biotechnol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"522-529","DOI":"10.1002\/mgg3.106","article-title":"The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy.","volume":"2","author":"C DiVincenzo","year":"2014","journal-title":"Mol Genet Genomic Med."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"109-16","DOI":"10.1523\/JNEUROSCI.1356-10.2010","article-title":"Strategy for genetic testing in Charcot-Marie-disease.","volume":"30","author":"L Miller","year":"2011","journal-title":"Acta Myol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"11388-97","DOI":"10.1523\/JNEUROSCI.1356-10.2010","article-title":"Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice.","volume":"30","author":"S Rangaraju","year":"2010","journal-title":"J Neurosci."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"248-53","DOI":"10.1016\/j.nmd.2006.12.008","article-title":"Ascorbic acid inhibits PMP22 expression by reducing cAMP levels.","volume":"17","author":"F Kaya","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"185-92","DOI":"10.1212\/01.wnl.0000336370.51010.a1","article-title":"Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.","volume":"72","author":"J England","year":"2009","journal-title":"Neurology."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2350-14-94","article-title":"Diagnostic laboratory testing for Charcot-Marie-Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies.","volume":"14","author":"R Ostern","year":"2013","journal-title":"BMC Med Genet."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"706-10","DOI":"10.1136\/jnnp-2012-302451","article-title":"Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing.","volume":"83","author":"S Murphy","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"22-33","DOI":"10.1002\/ana.22166","article-title":"Charcot-Marie-Tooth disease subtypes and genetic testing strategies.","volume":"69","author":"A Saporta","year":"2011","journal-title":"Ann Neurol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"522-7","DOI":"10.1038\/ejhg.2013.190","article-title":"Targeted next-generation sequencing reveals further genetic heterogeneity in axonal Charcot-Marie-Tooth neuropathy and a mutation in HSPB1.","volume":"22","author":"E Ylikallio","year":"2014","journal-title":"Eur J Hum Genet."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"332-43","DOI":"10.1002\/emmm.201100626","article-title":"Aminoacyl-tRNA synthetases in medicine and disease.","volume":"5","author":"P Yao","year":"2013","journal-title":"EMBO Mol Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"77-82","DOI":"10.1016\/j.ajhg.2009.12.005","article-title":"A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease.","volume":"86","author":"P Latour","year":"2010","journal-title":"Am J Hum Genet."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"197-202","DOI":"10.1038\/ng1727","article-title":"Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy.","volume":"38","author":"A Jordanova","year":"2006","journal-title":"Nat Genet."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"1293-9","DOI":"10.1086\/375039","article-title":"Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V.","volume":"72","author":"A Antonellis","year":"2003","journal-title":"Am J Hum Genet."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"560-6","DOI":"10.1016\/j.ajhg.2010.09.008","article-title":"Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy.","volume":"87","author":"H McLaughlin","year":"2010","journal-title":"Am J Hum Genet."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1247-9","DOI":"10.1136\/jnnp-2013-305049","article-title":"Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2.","volume":"84","author":"M Gonzalez","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"191-9","DOI":"10.1002\/humu.22210","article-title":"A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo.","volume":"34","author":"A Vester","year":"2013","journal-title":"Hum Mutat."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1363-71","DOI":"10.1002\/humu.22681","article-title":"Impaired function is a common feature of neuropathy-associated glycyl-tRNA synthetase mutations.","volume":"35","author":"L Griffin","year":"2014","journal-title":"Hum Mutat."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"e1002399","DOI":"10.1371\/journal.pgen.1002399","article-title":"Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels.","volume":"7","author":"W Motley","year":"2011","journal-title":"PLoS Genet."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"10397-406","DOI":"10.1523\/JNEUROSCI.1671-06.2006","article-title":"Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons.","volume":"26","author":"A Antonellis","year":"2006","journal-title":"J Neurosci."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"59-66","DOI":"10.1016\/j.tins.2009.11.001","article-title":"GARS axonopathy: not every neuron\u2019s cup of tRNA.","volume":"33","author":"W Motley","year":"2010","journal-title":"Trends Neurosci."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"437-472","DOI":"10.1007\/978-1-4939-0974-2_19","article-title":"Experimental Treatment of hereditary and acquired Neuropathies","author":"R Fledrich","year":"2014"},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"359-371","DOI":"10.1002\/(SICI)1097-0029(19980601)41:5<359::AID-JEMT3>3.0.CO;2-L","article-title":"Many facets of the peripheral myelin protein PMP22 in myelination and disease.","volume":"41","author":"R Naef","year":"1998","journal-title":"Micros Res Tech."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1055-61","DOI":"10.1038\/nm.3664","article-title":"Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A.","volume":"20","author":"R Fledrich","year":"2014","journal-title":"Nat Med."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"2594-602","DOI":"10.1021\/cb5005492","article-title":"Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease.","volume":"9","author":"J Inglese","year":"2014","journal-title":"ACS Chem Biol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"1205-13","DOI":"10.1021\/cb300048d","article-title":"Identification of drug modulators targeting gene-dosage disease CMT1A.","volume":"7","author":"S Jang","year":"2012","journal-title":"ACS Chem Biol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"224-36","DOI":"10.1016\/j.nbd.2014.06.023","article-title":"Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice.","volume":"70","author":"J Nicks","year":"2014","journal-title":"Neurobiol Dis."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"16140-52","DOI":"10.1523\/JNEUROSCI.1908-14.2014","article-title":"PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts.","volume":"34","author":"S Lee","year":"2014","journal-title":"J Neurosci."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"19599-604","DOI":"10.1073\/pnas.0907935106","article-title":"HDAC6 is a target for protection and regeneration following injury in the nervous system.","volume":"106","author":"M Rivieccio","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"968-74","DOI":"10.1038\/nm.2396","article-title":"HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.","volume":"17","author":"C d'Ydewalle","year":"2011","journal-title":"Nat Med."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"893-904","DOI":"10.1002\/ana.24004","article-title":"Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation.","volume":"74","author":"J Zhu","year":"2013","journal-title":"Ann Neurol."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"1-17","DOI":"10.1177\/1759091415569909","article-title":"Inducible HSP70 Is Critical in Preventing the Aggregation and Enhancing the Processing of PMP22.","volume":"7","author":"V Chittoor-Vinod","year":"2015","journal-title":"ASN Neuro."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"89-113","DOI":"10.1093\/bmb\/lds010","article-title":"Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease.","volume":"102","author":"R Fledrich","year":"2012","journal-title":"Br Med Bull."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"736-50","DOI":"10.1002\/glia.22638","article-title":"Nonuniform molecular features of myelinating Schwann cells in models for CMT1: distinct disease patterns are associated with NCAM and c-Jun upregulation.","volume":"62","author":"D Klein","year":"2014","journal-title":"Glia."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"780-92","DOI":"10.1242\/dmm.010942","article-title":"Loss of the E3 ubiquitin ligase LRSAM1 sensitizes peripheral axons to degeneration in a mouse model of Charcot-Marie-Tooth disease.","volume":"6","author":"L Bogdanik","year":"2013","journal-title":"Dis Model Mech."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"693-701","DOI":"10.1097\/NEN.0000000000000085","article-title":"Lack of neuropathy-related phenotypes in hint1 knockout mice.","volume":"73","author":"K Seburn","year":"2014","journal-title":"J Neuropathol Exp Neurol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"e67276","DOI":"10.1371\/journal.pone.0067276","article-title":"Axonal Transport Defects in a Mitofusin 2 Loss of Function Model of Charcot-Marie-Tooth Disease in Zebrafish.","volume":"8","author":"A Chapman","year":"2013","journal-title":"PLoS One."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"e01064","DOI":"10.7554\/eLife.01064","article-title":"Charcot-Marie-Tooth 2B mutations in rab7 cause dosage-dependent neurodegeneration due to partial loss of function.","volume":"2","author":"S Cherry","year":"2013","journal-title":"Elife."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"211-9","DOI":"10.1016\/j.nbd.2014.01.021","article-title":"Human Rab7 mutation mimics features of Charcot-Marie-Tooth neuropathy type 2B in Drosophila.","volume":"65","author":"K Janssens","year":"2014","journal-title":"Neurobiol Dis."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"180-9","DOI":"10.1016\/j.nbd.2014.04.020","article-title":"CMT-associated mutations in glycyl- and tyrosyl-tRNA synthetases exhibit similar pattern of toxicity and share common genetic modifiers in Drosophila.","volume":"68","author":"B Ermanoska","year":"2014","journal-title":"Neurobiol Dis."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"11782-7","DOI":"10.1073\/pnas.0905339106","article-title":"Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy.","volume":"106","author":"E Storkebaum","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"511-21","DOI":"10.1038\/mt.2013.250","article-title":"AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy.","volume":"22","author":"Z Sahenk","year":"2014","journal-title":"Mol Ther."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"209-19","DOI":"10.1089\/hum.2012.107","article-title":"Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.","volume":"24","author":"S Mussche","year":"2013","journal-title":"Hum Gene Ther."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"409-17","DOI":"10.1002\/embj.201387098","article-title":"iPS cells: a game changer for future medicine.","volume":"33","author":"H Inoue","year":"2014","journal-title":"EMBO J."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"678-84","DOI":"10.1016\/j.stem.2012.05.005","article-title":"Induced pluripotent stem cells: past, present, and future.","volume":"10","author":"S Yamanaka","year":"2012","journal-title":"Cell Stem Cell."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"748-50","DOI":"10.1016\/j.stem.2012.11.014","article-title":"Cellular reprogramming in pursuit of immortality.","volume":"11","author":"M Surani","year":"2012","journal-title":"Cell Stem Cell."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"497-505","DOI":"10.1038\/ncb0511-497","article-title":"Harnessing the potential of induced pluripotent stem cells for regenerative medicine.","volume":"13","author":"S Wu","year":"2011","journal-title":"Nat Cell Biol."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"1420-31","DOI":"10.1093\/hmg\/ddu556","article-title":"Let alIntermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.","volume":"24","author":"B Johnson-Kerner","year":"2014","journal-title":"Hum Mol Genet."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"190-9","DOI":"10.1016\/j.expneurol.2014.10.005","article-title":"Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties.","volume":"263","author":"M Saporta","year":"2015","journal-title":"Exp Neurol."},{"key":"ref-78","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-014-9577-1","article-title":"Pluripotent Stem Cells for Schwann Cell Engineering.","author":"M Ma","year":"2014","journal-title":"Stem Cell Rev."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"266-78","DOI":"10.5966\/sctm.2011-0042","article-title":"Human neural crest stem cells derived from human ESCs and induced pluripotent stem cells: induction, maintenance, and differentiation into functional schwann cells.","volume":"1","author":"Q Liu","year":"2012","journal-title":"Stem Cells Transl Med."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"203-12","DOI":"10.1038\/nprot.2012.156","article-title":"Directed differentiation of human pluripotent cells to neural crest stem cells.","volume":"8","author":"L Menendez","year":"2013","journal-title":"Nat Protoc."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"997-1008","DOI":"10.1007\/s10822-014-9762-y","article-title":"Bigger data, collaborative tools and the future of predictive drug discovery.","volume":"28","author":"S Ekins","year":"2014","journal-title":"J Comput Aided Mol Des."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"247-254","DOI":"10.1016\/j.drudis.2014.10.006","article-title":"Databases and collaboration require standards for human stem cell research.","volume":"20","author":"N Litterman","year":"2015","journal-title":"Drug Discov Today."},{"key":"ref-83","article-title":"NIH Blueprint Neurotherapeutics Network.","author":"Anon","year":"2014","journal-title":"Neuroscience research."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"261-70","DOI":"10.1016\/j.drudis.2008.11.015","article-title":"Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery.","volume":"14","author":"M Hohn","year":"2009","journal-title":"Drug Discov Today."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"298-310","DOI":"10.1016\/j.drudis.2011.02.016","article-title":"In silico repositioning of approved drugs for rare and neglected diseases.","volume":"16","author":"S Ekins","year":"2011","journal-title":"Drug Discov Today."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"2996-3004","DOI":"10.1021\/ci500445u","article-title":"Computational prediction and validation of an expert\u2019s evaluation of chemical probes.","volume":"54","author":"N Litterman","year":"2014","journal-title":"J Chem Inf Model."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"1545-53","DOI":"10.1212\/WNL.0000000000000919","article-title":"Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases.","volume":"83","author":"R Dortch","year":"2014","journal-title":"Neurology."},{"key":"ref-88","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308826","article-title":"CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.","author":"V Fridman","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"ref-89","article-title":"Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease","author":"Anon.","year":"2013"},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13023-014-0201-x","article-title":"Polytherapy with a combination of three repurposed drugs (PXT-3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.","volume":"9","author":"I Chumakov","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","article-title":"An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT-3003) in patients with Charcot-Marie-Tooth disease type 1A.","volume":"9","author":"S Attarian","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"2239-54","DOI":"10.1088\/0967-3334\/35\/11\/2239","article-title":"Intensity and duration of activity bouts decreases in healthy children between 7 and 13 years of age a new higher resolution method to analyze StepWatch Activity Monitor data.","volume":"35","author":"K Tulchin-Francis","year":"2014","journal-title":"Physiol Meas."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"41-5","DOI":"10.1519\/JPT.0b013e31820aa921","article-title":"Validity of the StepWatch Step Activity Monitor: preliminary findings for use in persons with Parkinson disease and multiple sclerosis.","volume":"34","author":"A Schmidt","year":"2011","journal-title":"J Geriatr Phys Ther."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"1003-17","DOI":"10.1016\/j.nmd.2014.06.431","article-title":"Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.","volume":"24","author":"M Mannil","year":"2014","journal-title":"Neuromuscul Disord."},{"key":"ref-95","first-page":"25-30","article-title":"Rehabilitation for Charcot-Marie-Tooth: a survey study of patients and familiar\/caregiver perspective and perception of efficacy and needs.","volume":"50","author":"L Padua","year":"2014","journal-title":"Eur J Phys Rehabil Med."},{"key":"ref-96","first-page":"7-9","article-title":"Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.","volume":"20","author":"J Beitz","year":"1996","journal-title":"J Natl Cancer Inst Monogr."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"1107-17","DOI":"10.1023\/A:1026187402267","article-title":"Quality of life terminology included in package inserts for US approved medications.","volume":"12","author":"S Shah","year":"2003","journal-title":"Qual Life Res."},{"key":"ref-98","doi-asserted-by":"publisher","first-page":"155-60","DOI":"10.1016\/j.jns.2013.10.029","article-title":"Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients.","volume":"336","author":"C Colomban","year":"2014","journal-title":"J Neurol Sci."},{"key":"ref-99","doi-asserted-by":"publisher","first-page":"793-7","DOI":"10.1212\/WNL.0000000000000173","article-title":"Effect of pain in pediatric inherited neuropathies.","volume":"82","author":"S Ramchandren","year":"2014","journal-title":"Neurology."},{"key":"ref-100","doi-asserted-by":"publisher","first-page":"265-271","DOI":"10.1016\/j.drudis.2012.10.007","article-title":"Four disruptive strategies for removing drug discovery bottlenecks.","volume":"18","author":"S Ekins","year":"2013","journal-title":"Drug Disc Today."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"191-8","DOI":"10.1111\/j.1529-8027.2011.00350.x","article-title":"Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.","volume":"16","author":"S Murphy","year":"2011","journal-title":"J Peripher Nerv Syst."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"16647-53","DOI":"10.1073\/pnas.1413965111","article-title":"Meal frequency and timing in health and disease.","volume":"111","author":"M Mattson","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"3614-8","DOI":"10.1016\/j.febslet.2008.09.040","article-title":"Ascorbic acid is a regulator of the intracellular cAMP concentration: old molecule, new functions?","volume":"582","author":"F Kaya","year":"2008","journal-title":"FEBS Lett."},{"key":"ref-104","article-title":"Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease.","year":"2013","journal-title":"Addex Therapeutics."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/4-53\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/4-53\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/4-53\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T08:06:37Z","timestamp":1543997197000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/4-53\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":104,"URL":"https:\/\/doi.org\/10.12688\/f1000research.6160.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.6604.r7842","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.6604.r7845","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.6604.r7845","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.6604.r7842","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/4-53\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.6604.r7842, Rhona Mirsky, Department of Cell and Developmental Biology, University College London, London, UK, 17 Mar 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-53\/v1#referee-response-7842","order":0,"name":"referee-response-7842","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.6604.r7845, Gerard Said, Department of Neurology, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, 75013, France, 01 Apr 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-53\/v1#referee-response-7845","order":1,"name":"referee-response-7845","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}